Lung Cancer Screening: Why, When, and How?

Florian J Fintelmann; Ravi V Gottumukkala; Shaunagh McDermott; Matthew D Gilman; Inga T Lennes; Jo-Anne O Shepard

doi:10.1016/j.rcl.2017.06.003

Lung Cancer Screening: Why, When, and How?

Radiol Clin North Am. 2017 Nov;55(6):1163-1181. doi: 10.1016/j.rcl.2017.06.003.

Authors

Florian J Fintelmann¹, Ravi V Gottumukkala², Shaunagh McDermott², Matthew D Gilman², Inga T Lennes³, Jo-Anne O Shepard²

Affiliations

¹ Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: fintelmann@mgh.harvard.edu.
² Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
³ Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA.

PMID: 28991558
DOI: 10.1016/j.rcl.2017.06.003

Abstract

This article explains the rationale of lung cancer screening with low-dose computed tomography and provides a practical approach to all relevant aspects of a lung cancer screening program. Imaging protocols, patient eligibility criteria, facility readiness, and reimbursement criteria are addressed step by step. Diagnostic criteria and Lung-RADS (Lung Computed Tomography Screening Reporting and Data System) nodule management pathways are illustrated with examples. Pearls and pitfalls for interpretation of lung cancer screening low-dose chest computed tomography are discussed.

Keywords: Low-dose computed tomography; Lung cancer screening; Lung-RADS; Screening.

Publication types

Review

MeSH terms

Early Detection of Cancer / methods*
Humans
Lung / diagnostic imaging
Lung Neoplasms / diagnostic imaging*
Radiation Dosage
Radiology Information Systems*
Tomography, X-Ray Computed / methods*